Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A. M., Sikic, B. I., Rahma, O. E., … Keler, T. (2018). Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results. In Journal of Clinical Oncology (Vol. 36, pp. 3001–3001). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.3001

Sanborn, Rachel E., Michael J. Pishvaian, Margaret K. Callahan, Amy M. Weise, Branimir I. Sikic, Osama E. Rahma, Daniel C. Cho, et al. “Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.” In Journal of Clinical Oncology, 36:3001–3001. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3001.

Sanborn RE, Pishvaian MJ, Callahan MK, Weise AM, Sikic BI, Rahma OE, et al. Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 3001–3001.

Sanborn, Rachel E., et al. “Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 3001–3001. Crossref, doi:10.1200/jco.2018.36.15_suppl.3001.

Sanborn RE, Pishvaian MJ, Callahan MK, Weise AM, Sikic BI, Rahma OE, Cho DC, Rizvi NA, Bitting RL, Starodub A, Jimeno A, Yellin MJ, Rawls T, Vitale L, Halim A, Zhang H, Keler T. Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 3001–3001.